SteadyMed Files Inter Partes Review to Invalidate United Therapeutics Patent
21 oct. 2015 07h00 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., Oct. 21, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed Provides Insights on Recent Corporate Developments and Reports Second Quarter 2015 Financial Results
13 août 2015 16h05 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (NASDAQ:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
SteadyMed Submits Application for Orphan Drug Designation for Trevyent(R) For Pulmonary Arterial Hypertension
07 mai 2015 07h00 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY) a specialty pharmaceutical company, today announced that it has submitted an application to the U.S. Food and Drug...